On Wednesday, Mankind Pharma said that it has agreed with Dr Reddy’s Laboratories (DRL) to acquire two of its brands – one asthma and one infant care brand. The deal size was not disclosed.

• Raymond Jumps 4% on Ex-BEL Chief’s Defence Appointment
• Supriya Lifescience Falls 12% on NDPS Act Proceedings
• Radico Hits Record High as Magic Moments Sales Soar 43%
• GK Energy Rallies on Rs 235.92 Crore Solar Pump Order
• Cupid Hits Fresh 52-Week High on Rs 128 Crore Block Deal

Combihale, a drug used for treating asthma and chronic obstructive pulmonary disease, has a category market size of Rs 900 crore, growing at 14 per cent (IQVIA). Daffy, a soap-free moisturizing bar for infants, operates in a market category valued at Rs 1000 crore and is growing at 18 per cent (IQVIA).

The company said that the acquisition of Combihale is expected to strengthen Mankind’s presence in the inhalation respiratory market segment.